NRx Pharmaceuticals (NRXP) Expected to Announce Earnings on Wednesday

NRx Pharmaceuticals (NASDAQ:NRXP) will likely be posting its quarterly earnings results after the market closes on Wednesday, March 26th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.30) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ NRXP opened at $2.07 on Tuesday. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01. The business has a fifty day moving average price of $2.77 and a two-hundred day moving average price of $2.04. The stock has a market capitalization of $35.02 million, a PE ratio of -0.97 and a beta of 1.22.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NRXP. D. Boral Capital restated a “buy” rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Thursday, March 20th. Finally, Ascendiant Capital Markets upped their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.